November 26, 2015 | BioLight Life Sciences Investments has entered into a joint financing agreement with two Asia-based venture capital firms to invest a total of $7.2 million into BioLight’s subsidiary, IOPtima. The financing will help IOPtima to continue the global commercialization of its innovative IOPtimate™ system used in the treatment of glaucoma, as well as to initiate a regulatory approval pathway process with the U.S. Food and Drug Administration, commencing 2016. Under the terms of the agreement, the unnamed investors and BioLight will invest an aggregate amount of US$6.0 million and US$1.2 million, respectively. The investments are being made on the basis of a US$13.5 million pre-money valuation for IOPtima. Upon completion of the private placement, BioLight will hold approximately 71% of IOPtima’s issued and outstanding shares.